比利时一家综合医院阿米卡星使用情况及氨基糖苷类耐药性的三年调查
Three-year survey of amikacin use and aminoglycoside resistance in a general hospital in Belgium.
作者信息
Vanhoof R, Hubrechts J M, Nyssen H J, Roebben E
机构信息
Laboratory of Medical Bacteriology, Institute Pasteur of Brabant, Brussels, Belgium.
出版信息
Eur J Clin Microbiol Infect Dis. 1988 Apr;7(2):183-5. doi: 10.1007/BF01963076.
The aim of the study was to evaluate the effect of intensive use of amikacin on the resistance levels to amikacin, gentamicin, tobramycin, netilmicin and dibekacin. The base-line resistance in the preamikacin phase (three months of amikacin use less than 1%; 676 isolates) was 1.0% for amikacin, 11.4% for gentamicin, 8.0% tobramycin, 6.2% for netilmicin and 8.3% for dibekacin. During the amikacin phase (36 months of average amikacin use of 89%; 6048 isolates) there was no significant change in aminoglycoside resistance except for dibekacin (from 8.3% to 10.9%, 0.05 greater than p greater than 0.02). Isolated amikacin resistance was not observed.
本研究的目的是评估强化使用阿米卡星对其自身以及庆大霉素、妥布霉素、奈替米星和地贝卡星耐药水平的影响。在使用阿米卡星前阶段（使用阿米卡星少于3个月；676株分离菌），阿米卡星的基线耐药率为1.0%，庆大霉素为11.4%，妥布霉素为8.0%，奈替米星为6.2%，地贝卡星为8.3%。在阿米卡星使用阶段（平均使用阿米卡星36个月，使用率89%；6048株分离菌），除地贝卡星外（从8.3%升至10.9%，P值大于0.02小于0.05），氨基糖苷类药物的耐药率无显著变化。未观察到单独的阿米卡星耐药情况。
Zotero 插件